Managing Pain Flares in Chronic Illness: Fibromyalgia, ME/CFS, and Long COVID

To understand how to manage a chronic pain flare, it is first necessary to define what a flare actually is in the context of complex chronic illness. For many patients, chronic pain is a daily reality, existing as a baseline level of discomfort that must be navigated constantly. A pain flare, however, represents a sudden, severe exacerbation of symptoms that pushes the pain far beyond this baseline, often accompanied by a cascade of other systemic issues like profound fatigue, cognitive impairment, and autonomic dysfunction. These episodes can last for hours, days, or even months, fundamentally altering a person's ability to function.

What makes these flares particularly challenging is their seemingly invisible nature. Unlike a broken bone or a visibly swollen joint, the pain experienced during a flare in conditions like fibromyalgia or ME/CFS often occurs without any obvious external signs of trauma or localized inflammation. This invisibility frequently leads to skepticism from friends, family, and even healthcare providers, adding a layer of emotional distress to the physical suffering. It is crucial to validate that this pain is a physiological reality, driven by measurable changes in how the nervous system processes sensory information.

During a flare, the body is essentially thrown into a state of severe sympathetic nervous system overdrive. The "fight-or-flight" response is activated, which can increase muscle tension, elevate heart rate, and further amplify the perception of pain. This systemic reaction explains why a pain flare is rarely just about pain; it is a full-body event that demands comprehensive management strategies aimed at soothing the entire nervous and immune network.

Historically, medical science categorized pain into two primary types: nociceptive and neuropathic. Nociceptive pain is the familiar pain caused by active tissue damage or acute inflammation, such as a sprained ankle or a burn. Neuropathic pain, on the other hand, results from direct damage to or disease of the somatosensory nervous system, such as a severed nerve or diabetic neuropathy. For decades, patients with chronic widespread pain were told their pain was "psychosomatic" because it did not neatly fit into either of these two categories.

Today, researchers recognize a third, distinct category of pain that perfectly describes the experience of patients with fibromyalgia, ME/CFS, and Long COVID: nociplastic pain. Nociplastic pain arises from altered nociception—meaning the pain processing pathways within the central nervous system have fundamentally changed how they interpret signals. There is no active tissue damage or severed nerve; instead, the "wiring" of the brain and spinal cord has become hyper-responsive, amplifying normal sensory input into severe pain.

Understanding the concept of nociplastic pain is a critical step in Chronic Pain in Complex Conditions: Mechanisms and Management Strategies. Because nociplastic pain is not driven by localized peripheral inflammation, traditional over-the-counter anti-inflammatory medications (NSAIDs) like ibuprofen are often entirely ineffective during a flare. Recognizing this distinction helps patients and providers pivot away from ineffective treatments and toward therapies that target the central nervous system directly.

The transition from an acute trigger—such as a viral infection, physical trauma, or period of intense psychological stress—to a state of chronic, flaring pain is a complex biological journey. In a healthy system, acute pain serves a vital protective function, warning the body of danger and encouraging rest while tissues heal. Once the threat has passed, the nervous system should theoretically return to a state of calm homeostasis.

However, in individuals who develop conditions like Long COVID or ME/CFS, this "off switch" fails to activate. The initial inflammatory response becomes chronic, locking the immune system and the nervous system into a continuous loop of cross-talk and hyper-vigilance. The body continues to act as though it is under acute threat, constantly deploying inflammatory cytokines and sensitizing pain receptors long after the initial trigger has resolved.

This chronic state means that the threshold for triggering a new pain flare is drastically lowered. Minor stressors—whether physical, cognitive, or environmental—that would normally be easily absorbed by a healthy nervous system are instead interpreted as massive threats, triggering a disproportionate and debilitating pain response. Understanding this mechanism is the foundation for developing effective, long-term flare management strategies.

The primary biological engine driving chronic pain flares in these complex illnesses is a phenomenon known as central sensitization. Central sensitization occurs when the central nervous system (CNS)—comprising the brain and spinal cord—becomes chronically hyperexcitable. Instead of accurately reporting sensory information from the body, the CNS acts like an amplifier whose volume dial is stuck at the maximum setting. This hyperexcitability fundamentally alters how neurons communicate across synapses.

When central sensitization takes hold, patients experience two hallmark clinical signs: allodynia and hyperalgesia. Allodynia is the experience of pain from stimuli that are not normally painful, such as the light touch of clothing against the skin or a gentle breeze. Hyperalgesia is an exaggerated pain response to a stimulus that is normally only mildly uncomfortable. During a pain flare, these sensitization mechanisms are operating at peak capacity, turning everyday interactions with the environment into sources of severe distress.

At the molecular level, this hyperexcitability is driven by the overactivation of specific receptors in the nervous system, particularly the N-methyl-D-aspartate (NMDA) receptors. When protective minerals like magnesium are depleted, these NMDA receptors allow massive amounts of calcium to flood into the neurons. This calcium influx triggers excitotoxicity, leading to severe sensory overload, cellular exhaustion, and the perpetuation of the central sensitization loop that defines a chronic pain flare.

Central sensitization does not occur in a vacuum; it is intimately linked to chronic neuroinflammation. The central nervous system has its own dedicated immune system, primarily composed of specialized cells called microglia and astrocytes. In a healthy brain, these glial cells act as housekeepers, clearing away cellular debris and supporting neuronal health. However, when triggered by systemic inflammation, viral fragments, or chronic stress, these cells transform into an activated, pro-inflammatory state.

Once activated, microglia and astrocytes release a flood of pro-inflammatory cytokines, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These chemical messengers bathe the neurons in an inflammatory soup, directly increasing neuronal excitability and suppressing the brain's natural inhibitory pathways (like GABA). This continuous glial cell activation is what keeps the nervous system inflamed and reactive, maintaining widespread pain and brain fog even after an initial viral infection has been cleared.

This neuroinflammatory process is a key focus in understanding Autoimmunity and Immune Dysregulation in Long COVID. Research has shown that the SARS-CoV-2 virus can disrupt the blood-brain barrier, allowing systemic inflammatory signals to cross into the brain and continuously stimulate these glial cells. This ongoing neuroimmune cross-talk explains why patients experience sudden, severe pain flares alongside cognitive impairments and profound fatigue.

Another critical player in the biology of pain flares is the mast cell. Mast cells are a type of white blood cell that act as the immune system's first responders, heavily concentrated in tissues that interface with the external environment and in close proximity to peripheral nerves. When triggered, mast cells degranulate, releasing a massive payload of chemical mediators, including histamine, tryptase, prostaglandins, and substance P.

In patients with Mast Cell Activation Syndrome (MCAS)—a condition frequently overlapping with fibromyalgia and Long COVID—these cells become hyper-reactive and unstable. The release of mast cell mediators can destabilize the blood-brain barrier, acting as the "immune gateway" to the brain. Once these mediators cross into the central nervous system, they directly activate the microglia, creating a self-perpetuating, feed-forward loop of neuroinflammation and pain amplification.

In the peripheral nervous system, mast cells are intimately connected to nociceptors (pain-sensing nerves). When mast cells degranulate, they release neuro-sensitizing molecules like calcitonin gene-related peptide (CGRP), which directly stimulate and inflame sensory neurons. Over time, this constant bombardment contributes to small-fiber neuropathy, a common driver of neuropathic pain and dysautonomia, ensuring that the body remains locked in a state of chronic pain vulnerability.

Fibromyalgia is perhaps the most well-known condition characterized by chronic, widespread nociplastic pain and frequent pain flares. Historically viewed as a purely psychosomatic disorder, it is now firmly established as a central sensitivity syndrome. Patients with fibromyalgia experience a baseline of diffuse musculoskeletal pain that can rapidly escalate into a severe flare when triggered by physical exertion, poor sleep, or emotional stress.

Recent genetic studies have provided robust evidence that fibromyalgia is primarily a central nervous system disorder. A massive multi-ancestry genome-wide association study discovered numerous risk loci and prioritized CNS-related genes, showing that fibromyalgia heritability is enriched exclusively in brain tissues and neuronal cell types. This genetic vulnerability helps explain why certain individuals are predisposed to developing severe central sensitization and frequent pain flares following an environmental trigger.

Understanding this condition is essential for effective management, as detailed in our guide on Fibromyalgia: What It Is, How It Feels, and What Helps. During a fibromyalgia flare, patients often report that their pain feels like a deep, burning ache that migrates across the body, accompanied by severe allodynia where even the weight of a blanket can feel agonizing. This widespread sensitization requires a multifaceted management approach that targets the brain rather than just the peripheral muscles.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, debilitating multisystem disease where pain flares are inextricably linked to a defining symptom: post-exertional malaise (PEM). PEM is a condition where symptoms—including debilitating pain, profound fatigue, and cognitive dysfunction—worsen disproportionately after minor physical or mental exertion. In ME/CFS, a pain flare is often the direct result of a "crash" triggered by exceeding the body's broken energy limits.

A key clinical finding of PEM is that pain flares and fatigue do not always happen immediately. According to clinical guidelines from the CDC, symptoms typically worsen 12 to 48 hours after the triggering activity. This delayed onset makes it incredibly difficult for patients to immediately identify what caused the flare, complicating efforts to manage activity levels. During an ME/CFS crash, patients frequently experience deep muscle and joint pain, migraine-like headaches, and burning peripheral nerve pain.

The severity of these flares cannot be overstated. Approximately 25% of all people with ME/CFS have a severe disease presentation, meaning they are entirely housebound or bedbound. For these individuals, the "trigger" for a massive pain flare might be as minimal as chewing food, tolerating normal room lighting, or speaking a few words. This profound energy deficit and subsequent pain amplification highlight the critical need for strict pacing strategies.

The emergence of Long COVID has brought unprecedented attention to the mechanisms of post-viral chronic pain. Since the pandemic began, researchers have noted a striking clinical overlap between the post-acute sequelae of COVID-19 and pre-existing conditions like fibromyalgia and ME/CFS. It is now widely hypothesized that the SARS-CoV-2 virus triggers systemic neuroinflammation, which in turn drives central sensitization, resulting in chronic, widespread nociplastic pain.

Recent clinical data highlights the soaring rates of central sensitization following COVID-19 infection. In comprehensive surveys of patients suffering from post-COVID symptoms, an astounding 70% of respondents had scores consistent with fibromyalgia and central sensitization features. The viral spike protein has been shown to directly activate mast cells and toll-like receptors (TLR4), initiating a massive release of pro-inflammatory mediators that sensitize peripheral nerves and disrupt the blood-brain barrier.

This post-viral immune dysregulation means that Long COVID patients frequently experience severe musculoskeletal pain flares, neuropathy, and dysautonomia. The molecular "switches" that control inflammation fail to turn off after the acute viral infection is cleared, leading to chronic neuropathic pain and extreme post-exertional malaise. Recognizing Long COVID pain as a nociplastic condition fundamentally changes how it must be treated, shifting the focus away from traditional painkillers and toward neuro-immune modulation.

Living with chronic pain flares means navigating a world filled with invisible landmines. Because the nervous system in conditions like fibromyalgia and ME/CFS is in a state of chronic hyperexcitability, the threshold for triggering a flare is drastically lowered. Activities that previously caused no issues in healthy individuals can now provoke severe, debilitating pain. These triggers are highly individualized and can be broadly categorized into physical, cognitive, sensory, and orthostatic stressors.

Physical triggers include everyday activities of daily living (ADLs) such as showering, cooking, light cleaning, or walking. However, cognitive and emotional exertion use significant cellular energy and are equally potent triggers. Reading, writing, working on a computer, or engaging in long, emotionally taxing conversations can initiate a physical pain flare just as easily as a brisk walk. Sensory triggers, such as exposure to bright lights, loud environments, or strong chemical odors, can also overwhelm a sensitized nervous system.

Furthermore, because many patients with these complex conditions also suffer from orthostatic intolerance (such as Postural Orthostatic Tachycardia Syndrome, or POTS), simply sitting upright or standing for prolonged periods can trigger a severe flare. The erratic heart rates and blood pressure fluctuations associated with dysautonomia starve the brain of stable blood flow, exacerbating symptoms of fatigue, sensory overload, and widespread pain.

The impact of chronic pain flares extends far beyond physical discomfort; it exacts a massive cognitive and emotional toll. When a flare strikes, the brain is flooded with nociceptive signals and inflammatory cytokines, which directly impairs cognitive function. Patients frequently experience severe "brain fog," characterized by memory lapses, difficulty concentrating, and an inability to process complex information. This cognitive impairment can make it nearly impossible to work, manage household tasks, or even articulate symptoms to a healthcare provider.

Emotionally, the unpredictability of pain flares breeds a profound sense of anxiety and hyper-vigilance. Patients often live in fear of the next flare, constantly analyzing their environment and their bodily sensations for early warning signs. This chronic stress directly impacts the hypothalamic-pituitary-adrenal (HPA) axis and the vagus nerve, worsening neuroinflammation and creating a vicious cycle where the fear of pain actually exacerbates the biological mechanisms of central sensitization.

The isolation that accompanies chronic pain is another significant emotional burden. Because the pain is invisible and flares can force patients to cancel plans at the last minute, maintaining social relationships becomes incredibly difficult. Many patients report feeling profound grief for their pre-illness lives and frustration with a medical system that often fails to provide adequate support or validation for their suffering.

One of the most common and destructive patterns in the daily lives of chronic illness patients is the "boom-and-bust" cycle. When patients experience a "good day" with lower baseline pain, there is a natural, overwhelming temptation to catch up on neglected chores, work, or social activities. They push themselves to accomplish as much as possible while they have the energy, essentially "booming" their activity levels.

Unfortunately, because of the delayed nature of post-exertional malaise (PEM) and central sensitization, this overexertion inevitably leads to a massive "bust." Within 12 to 48 hours, the nervous system becomes overwhelmed, triggering a severe pain flare and profound fatigue that can leave the patient bedbound for days or weeks. This cycle of overactivity followed by forced, prolonged rest is physically damaging and emotionally demoralizing.

Breaking the boom-and-bust cycle is one of the primary goals of chronic illness management. It requires a fundamental shift in how patients view their energy and activity levels, moving away from symptom-driven behavior (doing more when you feel good) toward strictly regulated, proactive energy management. This behavioral shift is incredibly challenging but absolutely essential for stabilizing the nervous system and reducing the frequency of severe pain flares.

Effectively managing chronic pain flares requires accurate measurement and tracking, which can be challenging given the subjective nature of pain. However, researchers and clinicians have developed several validated scales and questionnaires designed specifically to quantify the severity of central sensitization and nociplastic pain. These tools help bridge the communication gap between patients and providers, providing objective data points for an invisible symptom.

One of the most important tools in this context is the Central Sensitization Inventory (CSI). The CSI is a comprehensive questionnaire that assesses a wide range of somatic and emotional symptoms associated with central sensitivity syndromes, including unrefreshing sleep, cognitive difficulties, and sensitivity to light and sound. A high score on the CSI strongly indicates that a patient's pain is driven by central nervous system hyperexcitability rather than peripheral tissue damage, guiding the clinician toward appropriate neuro-modulating treatments.

Other useful clinical tools include the Fibromyalgia Impact Questionnaire (FIQ) and the Brief Pain Inventory (BPI). These scales measure not only the intensity of the pain but also how significantly the pain interferes with daily activities, mood, and sleep. By completing these questionnaires regularly, patients can provide their healthcare team with a clear, longitudinal picture of their symptom trajectory, helping to evaluate the effectiveness of ongoing management strategies.

In recent years, wearable technology has revolutionized how patients with ME/CFS, Long COVID, and fibromyalgia track and manage their symptoms. Devices like smartwatches and fitness trackers provide continuous, objective data on physiological metrics that correlate strongly with nervous system health and impending pain flares. For patients struggling with post-exertional malaise (PEM), these devices are essential tools for proactive pacing.

Heart Rate (HR) and Heart Rate Variability (HRV) are two of the most critical metrics to monitor. In patients with dysautonomia and central sensitization, the heart rate often spikes inappropriately during minor exertion, signaling that the body has crossed its anaerobic threshold. By setting heart rate alarms on their wearables, patients can receive real-time alerts to stop and rest before they trigger a pain flare. Similarly, a drop in HRV—which measures the variation in time between heartbeats—indicates that the nervous system is stuck in a sympathetic "fight-or-flight" state, serving as an early warning sign of an impending crash.

In clinical research settings, the 2-day Cardiopulmonary Exercise Test (2-day CPET) is used to objectively measure the profound physiological abnormalities associated with PEM. While not recommended for routine clinical use due to the high risk of triggering a severe, long-lasting crash, the 2-day CPET has provided undeniable proof that the fatigue and pain flares in ME/CFS and Long COVID are rooted in measurable metabolic and cellular dysfunction, not deconditioning.

While wearable technology provides excellent physiological data, a comprehensive symptom diary remains one of the most effective ways to identify the specific, individualized triggers of chronic pain flares. Because conditions like ME/CFS feature a delayed onset of symptoms (often 12 to 48 hours after exertion), relying on memory alone to identify what caused a flare is frequently inaccurate and frustrating.

A detailed symptom diary should track multiple variables simultaneously: daily activity levels (including cognitive and emotional exertion), sleep quality, dietary intake, weather/barometric pressure changes, and the intensity and location of pain. By logging this data consistently over several weeks, patients and their care teams can begin to identify patterns and correlations that would otherwise remain hidden. For example, a patient might discover that their severe weekend pain flares are actually triggered by the cognitive strain of a weekly Thursday afternoon meeting.

There are numerous digital apps designed specifically for tracking complex chronic illnesses, offering customizable tags for specific symptoms and triggers. These tools can automatically generate reports and graphs, making it easier to visualize the "boom-and-bust" cycle and adjust pacing strategies accordingly. Consistent tracking empowers patients to take an active role in their management, transforming unpredictable flares into somewhat predictable, and therefore preventable, events.

The cornerstone of managing pain flares in ME/CFS, Long COVID, and fibromyalgia is pacing. Pacing is an evidence-based behavioral strategy that involves carefully balancing rest and activity to keep the body within its specific "energy envelope." By preventing the nervous and immune systems from becoming overwhelmed, pacing directly reduces the frequency and severity of post-exertional malaise (PEM) and central sensitization flares.

It is crucial to distinguish between safe and harmful pacing strategies. Symptom-contingent pacing is the standard of care; it relies on stopping activity based on internal, observable symptoms and heart rate metrics to conserve energy. In contrast, quota-contingent pacing, such as Graded Exercise Therapy (GET), encourages patients to gradually increase activity to meet a predetermined goal, ignoring warning symptoms. Current clinical consensus and advocacy guidelines strongly warn against GET, as it has been consistently proven to cause significant harm, provoke severe PEM, and permanently reduce functional capacity in these patient populations.

To implement effective pacing, patients often use the "Traffic Light System." Green means symptoms are stable, and light activity is safe. Yellow indicates mild warning signs—such as creeping pain, slight brain fog, or an elevated heart rate—which serve as an immediate cue to stop and rest. Red indicates crash territory, where deep, radical rest in a low-sensory environment is mandatory. By strictly adhering to these boundaries and avoiding the temptation to push through the "yellow" warnings, patients can slowly stabilize their hyper-reactive nervous systems.

Another practical pacing tool is task fractionation, which involves breaking daily chores into bite-sized segments. Instead of preparing a meal all at once, a patient might chop vegetables while seated, take a 20-minute rest, and then return to cook. This approach prevents the sustained exertion that triggers metabolic exhaustion and subsequent pain flares, allowing patients to accomplish necessary tasks without borrowing energy from tomorrow.

Because nociplastic pain is driven by central nervous system hyperexcitability rather than peripheral tissue damage, standard over-the-counter pain relievers (like ibuprofen or acetaminophen) are often entirely ineffective for chronic pain flares. Instead, pharmacological management must focus on calming the central nervous system, modulating glial cell activity, and restoring autonomic balance.

One of the most promising off-label treatments for central sensitization and neuroinflammation is Low Dose Naltrexone (LDN). Typically prescribed at very low doses (1 to 4.5 mg per day), LDN acts as a powerful glial cell modulator. It blocks Toll-like receptor-4 (TLR4), which inhibits the activation of microglia in the brain and spinal cord, thereby reducing the production of pro-inflammatory cytokines like TNF-α and IL-6. Clinical studies, including a 14-year retrospective analysis by the Mayo Clinic, have shown that LDN can provide significant pain reduction for patients with fibromyalgia and chronic neuropathy.

Other pharmacological approaches target the neurotransmitters involved in pain signaling. Medications such as serotonin and norepinephrine reuptake inhibitors (SNRIs) or gabapentinoids are frequently used to enhance the brain's natural descending inhibitory pain pathways and reduce neuronal hyperexcitability. However, because patients with ME/CFS and Long COVID often have severe chemical sensitivities and paradoxical reactions to medications, these drugs must be introduced at very low doses and titrated slowly under the close supervision of a knowledgeable healthcare provider.

In addition to daily medications, experts recommend creating a proactive "Flare Plan." This is a customized checklist of interventions—such as specific rescue medications, heat or cold therapy, pelvic floor stretches, or targeted vagus nerve breathing exercises—that a patient can deploy immediately when a flare strikes. Having a pre-written plan is essential because severe pain impairs cognitive function, making it difficult to make treatment decisions in the midst of a crisis.

Emerging neuronutritional approaches offer another vital layer of support for managing chronic pain flares. These interventions target cellular health, mitochondrial function, and oxidative stress, all of which are frequently impaired in complex chronic illnesses. By providing the body with the specific biochemical tools it needs to repair cellular damage and modulate inflammation, targeted supplementation can help raise the threshold for pain flares.

Coenzyme Q10 (CoQ10) is a critical antioxidant required by the mitochondria to produce cellular energy (ATP). Patients with fibromyalgia and ME/CFS often exhibit severe mitochondrial dysfunction and CoQ10 depletion, leading to cellular exhaustion and increased oxidative stress. Supplementing with CoQ10 can help mitigate this oxidative damage, reduce central sensitization, and support overall energy production. For a deeper dive into this mechanism, explore our guide: Can CoQ10 Support Energy Levels for Long COVID and ME/CFS Patients?.

Curcumin, the active polyphenol found in turmeric, is another powerful tool for managing systemic inflammation. It works by inhibiting Nuclear Factor-kappa B (NF-κB), the master protein complex responsible for triggering inflammatory cascades, thereby suppressing the release of inflammatory mediators from spinal glia. Because standard curcumin is poorly absorbed, utilizing highly bioavailable formulations is essential for clinical efficacy. Learn more in our article: Can Curcumin Support Brain Fog and Inflammation in Long COVID and ME/CFS?.

Functional medicine approaches frequently combine these supplements for a synergistic effect. Curcumin aggressively targets and downregulates the systemic inflammatory response, while CoQ10 simultaneously repairs mitochondrial damage and fuels cellular energy. Together, they offer a comprehensive strategy for tackling chronic pain from both a central and systemic level, supporting the body's natural healing processes without the severe side effects often associated with traditional pain medications.

Living with chronic pain flares in the context of fibromyalgia, ME/CFS, or Long COVID is an incredibly arduous journey, often compounded by a medical system that struggles to understand invisible, systemic illnesses. It is vital to remember that your pain is real, your fatigue is measurable, and your symptoms are rooted in documented biological mechanisms like central sensitization and neuroinflammation. You are not imagining the severity of your flares, and you are not to blame for the unpredictability of your condition.

Validation is a crucial first step in healing. When you understand that your nervous system is biologically stuck in a state of hyper-vigilance, you can begin to release the guilt and frustration associated with the "boom-and-bust" cycle. Acknowledging the physiological reality of nociplastic pain allows you to pivot away from treatments that don't work and toward evidence-based strategies—like pacing, nervous system regulation, and targeted neuro-immune support—that actually address the root causes of your symptoms.

While there is currently no definitive cure for these complex chronic conditions, significant improvements in quality of life are entirely possible. By learning to track your unique triggers, strictly managing your energy envelope, and utilizing advanced pharmacological and nutritional tools, you can slowly calm your overactive nervous system, reduce the frequency and severity of pain flares, and reclaim a sense of stability in your daily life.

Managing complex chronic pain requires a multidisciplinary approach and a healthcare team that truly understands the nuances of central sensitivity syndromes and post-viral illness. It is essential to work with providers who respect your lived experience, understand the dangers of graded exercise therapy, and are willing to explore off-label treatments like Low Dose Naltrexone and targeted cellular supplementation.

Always consult with a qualified healthcare provider before starting or stopping any medication, supplement, or physical therapy regimen. Because conditions like Long COVID and ME/CFS often involve severe chemical sensitivities and complex autonomic dysfunction, treatments must be highly individualized and carefully monitored to prevent adverse reactions and ensure long-term safety.

If you are struggling to navigate chronic pain flares and are looking for specialized, compassionate care, explore RTHM's comprehensive resources and clinical support. Our team is dedicated to providing science-backed, patient-centric care for complex chronic conditions, helping you build a personalized management plan that honors your body's unique needs and supports your path toward a better quality of life.